| γH2AX | Histone H2AX phosphorylated on Ser 139 |
| 10H | Clone mouse monoclonal anti-PAR antibody (Tulip #1020) |
| 3AB | 3-Aminobenzamide (PARP inhibitor) |
| 3i | Inhibition of DNA-PK, LigIV, and ATM |
| 4-ANI | 4-Amino-1,8-naphthalimide |
| 53BP1 | p53 binding protein 1 |
| AG14361 | 2-[4-[(dimethylamino)methyl]phenyl]-1,3,10-triazatricyclo[6.4.1.04,13]trideca-2,4,6,8(13)-tetraen-9-one (PARP-1i) |
| ATM | Ataxia telangiectasia mutated |
| ATMi | ATM inhibitor |
| ATR | Ataxia telangiectasia and Rad3-related protein |
| ATRi | ATR inhibitor |
| AZ20 | 4{4-[(3R)3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole |
| BER | Base excision repair |
| BLEO | Bleomycin |
| BRCA1/2 | Breast cancer gene 1 or 2 |
| CDKN2 | Cyclin-dependent kinase inhibitor 2 |
| CHK1 | Checkpoint kinase 1 |
| CHO9 | Chinese hamster ovary 9 cell line |
| C-NHEJ | Canonic-non-homologous End Joining |
| DAPI | 4′,6-diamidino-2-phenylindole (fluorescent DNA marker) |
| DDI | DNA damage index |
| DDR | DNA damage response |
| DEA | 6,9-Diamino-2-ethoxyacridine-DL-lactate monohydrate |
| DMSO | Dimethyl sulfoxide |
| DNA-PK | DNA-dependent protein kinase |
| DNA-PKi | DNA-PK inhibitor |
| DSBs | Double-strand breaks |
| E-64 | trans-Poxysuccinyl-l-leucylamido-(4-guanidino) butane |
| E7016 | 10-((4-Hydroxypiperidin-1-yl)methyl)chromeno[4,3,2-de]phthalazin-3(2H)-one (PARPi) |
| EB | 5′-deoxy-5′-[4-[2-[(2,3-dihydro-1oxo-1H-isoindol-4-yl)amino]-2-oxoethyl]-1-piperazinyl]-5′-oxoadenosine dihydrochloride (PARPi) |
| FBS | Fetal bovine serum |
| HeLa | Henrietta Lacks human epithelial carcinoma cell line |
| HEp-2 | Human epithelial type 2 cells |
| HNSCC | Head and neck squamous cell carcinomas |
| HR | Homologous recombination |
| IC50 | The half-maximal inhibitory concentration |
| ICF | Inmunocytofluorescence |
| INO1001 | 3-Aminobenzamide (PARP inhibitor) |
| IR | Ionizing radiation |
| KU-0060648 | 4-Ethyl-N-[4-[2-(4-morpholinyl)-4-oxo-4H-1-benzopyran-8-yl]-1-dibenzothienyl]-1-piperazineacetamide (DNA-PKi) |
| KU55933 | 2-Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one |
| KU70/80 | Ku heterodimer: Ku70 (XRCC6) and Ku80 (XRCC5) |
| LigIII | DNA ligase 3 |
| LigIV | DNA ligase 4 |
| LigIVi | LigIV inhibitor |
| MAPK | Mitogen-activated protein kinase |
| MEM | Minimum essential medium |
| MMEJ | Microhomology-mediated end joining |
| MMS | Methylmethanosulfonate |
| MRE11 | Complex consisting of meiotic recombination 11 |
| Mst-1 | Macrophage-stimulating 1 (mitogen-activated protein kinase) |
| MTT | 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
| NAD+ | Nicotinamide adenine dinucleotide |
| Nam | Nicotinamide |
| NMuMG | Nontransformed mouse mammary gland epithelial cell line |
| OLA | Olaparib (Lynparza, AZD-2281; PARP-1/2 & 3 inhibitor); IUPAC name:4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one |
| p38 | A class of MAPK |
| PAR | Poly(ADP-ribose) |
| PARG | Poly-ADP-glicohidrolase |
| PARP | Poly(ADP-ribosyl) polymerase |
| PARPis | PARP inhibitors |
| PARylation | Poly(ADP-ribosylation) |
| PBS | Phosphate-buffered saline |
| PFA | Paraformaldehyde |
| Polβ | DNA polymerase β |
| Prexacertib | 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile (CHK1 inhibitor) |
| PtK2 | Male rat kangaroo kidney epithelial cell |
| RT | Room temperature |
| SSBs | Single-strand breaks |
| TNKS | Tankyrase |
| UV-C | Ultraviolet C radiation |
| VE-821 | 3-amino-6-(4-methylsulfonylphenyl)-N-phenylpyrazine-2-carboxamide (ATRi) |
| VE-822 | 3-[3-[4-(methylaminomethyl)phenyl]-1,2-oxazol-5-yl]-5-(4-propan-2-ylsulfonylphenyl)pyrazin-2-amine (ATRi) |
| VERO | African green monkey kidney epithelial cell line |
| VRK1 | Vaccinia-related kinase 1 |
| WBWEE1 | Western BlotsG2 checkpoint kinase |
| XRCC1 | X-ray repair cross-complementing protein 1 |